PASG RSI Chart
Last 7 days
14.0%
Last 30 days
-3.7%
Last 90 days
35.4%
Trailing 12 Months
25%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2022 | 0 | 985.0K | 1.6M | 2.3M |
2021 | 0 | 0 | 0 | 343.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 13, 2024 | borthwick kathleen | sold | -1,425 | 0.97 | -1,470 | svp, interim cfo |
Feb 13, 2024 | forman mark s | sold | -1,588 | 0.97 | -1,638 | chief medical officer |
Feb 10, 2024 | borthwick kathleen | acquired | - | - | 4,000 | svp, interim cfo |
Feb 10, 2024 | forman mark s | acquired | - | - | 5,000 | chief medical officer |
Jan 02, 2024 | cale edgar b. | sold | -14,389 | 0.91 | -15,813 | gc & corporate secretary |
Jan 02, 2024 | borthwick kathleen | sold | -9,711 | 0.91 | -10,672 | svp, interim cfo |
Jan 02, 2024 | forman mark s | sold | -14,389 | 0.91 | -15,813 | chief medical officer |
Dec 31, 2023 | borthwick kathleen | acquired | - | - | 30,000 | svp, interim cfo |
Dec 31, 2023 | forman mark s | acquired | - | - | 50,000 | chief medical officer |
Dec 31, 2023 | cale edgar b. | acquired | - | - | 50,000 | gc & corporate secretary |
Which funds bought or sold PASG recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 25, 2024 | Bank of New York Mellon Corp | sold off | -100 | -13,783 | - | -% |
Apr 25, 2024 | SIMPLEX TRADING, LLC | sold off | -100 | -2,000 | - | -% |
Apr 16, 2024 | TSFG, LLC | unchanged | - | - | - | -% |
Apr 12, 2024 | DLK Investment Management, LLC | unchanged | - | 21,760 | 86,400 | 0.04% |
Apr 05, 2024 | CWM, LLC | unchanged | - | - | - | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 0.05 | 711,304 | 2,039,070 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 95.97 | 36,269 | 54,330 | -% |
Feb 26, 2024 | Virtu Financial LLC | new | - | 68,000 | 68,000 | -% |
Feb 15, 2024 | BARCLAYS PLC | unchanged | - | 4,000 | 13,000 | -% |
Feb 14, 2024 | Royal Bank of Canada | added | 847 | - | - | -% |
Unveiling Passage Bio Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Passage Bio Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 42.6B | 6.8B | -9.05 | 6.23 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.6B | 1.8B | -42.16 | 10.15 | ||||
BMRN | 15.4B | 2.5B | 74.78 | 6.22 | ||||
INCY | 11.8B | 3.7B | 19.75 | 3.19 | ||||
MID-CAP | ||||||||
APLS | 5.8B | 396.6M | -10.91 | 14.55 | ||||
BBIO | 4.5B | - | -6.86 | 60.35 | ||||
AXSM | 3.5B | 270.6M | -14.59 | 12.9 | ||||
ARWR | 2.9B | 240.7M | -9.65 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.97 | 3.88 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 25.14 | 4.51 | ||||
NVAX | 600.4M | 983.7M | -1.1 | 0.61 | ||||
CRBP | 374.0M | 881.7K | -8.38 | 466.16 | ||||
INO | 268.8M | 4.9M | -1.99 | 55.23 | ||||
IBIO | 5.8M | 2.1M | -0.21 | 2.14 |
Passage Bio Inc News
Income Statement (Quarterly) | |||||||
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2021Q4 | 2021Q3 | 2021Q2 |
Revenue | 42.2% | 1,173,000 | 825,000 | 270,000 | 228,000 | 186,000 | 99,000 |
S&GA Expenses | -0.7% | 10,587,000 | 10,664,000 | 12,991,000 | 17,192,000 | 14,978,000 | 15,422,000 |
Net Income | -1.4% | -27,071,000 | -26,701,000 | -39,542,000 | -51,154,000 | -46,915,000 | -48,435,000 |
Net Income Margin | 33.1% | -59.99 | -89.63 | -138 | -540 | - | - |
Free Cashflow | -2.7% | -24,021,000 | -23,395,000 | -26,083,000 | -30,775,000 | -41,056,000 | -24,330,000 |
Balance Sheet | |||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2018Q4 |
Assets | -11.1% | 151 | 169 | 194 | 213 | 244 | 270 | 299 | 333 | 355 | 391 | 440 | 465 | 328 | 359 | 378 | 392 | 179 | 33.00 |
Current Assets | -13.1% | 118 | 136 | 154 | 172 | 197 | 223 | 251 | 283 | 325 | 366 | 419 | 451 | 317 | 350 | 368 | 382 | 166 | 33.00 |
Cash Equivalents | -35.3% | 22.00 | 34.00 | 30.00 | 33.00 | 35.00 | 63.00 | 91.00 | 102 | 129 | 163 | 215 | 250 | 135 | 201 | 353 | 367 | 159 | 25.00 |
Net PPE | -4.8% | 15.00 | 16.00 | 20.00 | 22.00 | 23.00 | 23.00 | 24.00 | 24.00 | 24.00 | 18.00 | 13.00 | 7.00 | 3.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 |
Liabilities | -8.7% | 39.00 | 43.00 | 43.00 | 43.00 | 42.00 | 46.00 | 51.00 | 52.00 | 36.00 | 29.00 | 37.00 | 24.00 | 23.00 | 20.00 | 15.00 | 6.00 | 4.00 | 3.00 |
Current Liabilities | -17.5% | 16.00 | 20.00 | 20.00 | 17.00 | 18.00 | 22.00 | 27.00 | 27.00 | 29.00 | 22.00 | 31.00 | 19.00 | 21.00 | 19.00 | 14.00 | 5.00 | 4.00 | 0.00 |
Shareholder's Equity | -11.9% | 111 | 126 | 150 | 170 | 201 | 224 | 248 | 281 | 319 | 362 | 402 | 442 | 305 | 339 | 363 | 387 | - | - |
Retained Earnings | -2.9% | -594 | -577 | -550 | -526 | -492 | -465 | -438 | -399 | -356 | -305 | -258 | -209 | -170 | -131 | -103 | -76.20 | -58.66 | -13.03 |
Additional Paid-In Capital | 0.2% | 706 | 704 | 701 | 698 | 695 | 691 | 688 | 682 | 675 | 667 | 660 | 651 | 476 | 471 | 467 | 463 | 2.00 | 1.00 |
Shares Outstanding | 0.2% | 55.00 | 55.00 | 55.00 | 55.00 | 55.00 | 54.00 | 54.00 | 54.00 | 54.00 | 53.00 | 54.00 | 51.00 | - | - | - | - | - | - |
Float | - | - | - | 47.00 | - | - | - | 101 | - | - | - | 483 | - | - | - | 772 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -1.8% | -19,516 | -19,163 | -17,139 | -22,446 | -24,021 | -23,395 | -26,083 | -44,711 | -30,775 | -41,056 | -24,330 | -30,718 | -29,424 | -17,530 | -11,715 | -21,851 | -17,478 | -11,424 | -10,780 | -214 | - |
Share Based Compensation | -44.4% | 1,570 | 2,824 | 3,743 | 2,784 | 3,477 | 2,862 | 6,278 | 6,337 | 7,575 | 6,815 | 8,561 | 9,740 | 4,324 | 4,033 | 3,855 | 2,368 | 1,036 | 95.00 | 92.00 | 231 | - |
Cashflow From Investing | -66.1% | 7,600 | 22,451 | 13,969 | 21,217 | -3,358 | -4,758 | 16,004 | 17,311 | -3,605 | -11,555 | -10,257 | -20,397 | -36,546 | -135,367 | -94.00 | -99.00 | -43.00 | -109 | -657 | -884 | - |
Cashflow From Financing | - | 46.00 | - | - | - | -588 | -408 | -406 | 49.00 | 455 | 44.00 | 523 | 165,634 | 402 | 44.00 | -1,596 | 229,904 | -799 | 109,938 | 46,306 | 20,157 | - |
Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses: | ||
Research and development | $ 61,419 | $ 86,053 |
Acquired inprocess research and development | 3,000 | |
General and administrative | 41,580 | 49,341 |
Impairment of long-lived assets | 5,390 | |
Loss from operations | (108,389) | (138,394) |
Other income (expense), net | 6,327 | 2,269 |
Net loss | $ (102,062) | $ (136,125) |
Per share information: | ||
Net loss per share of common stock, basic | $ (1.86) | $ (2.50) |
Net loss per share of common stock, diluted | $ (1.86) | $ (2.50) |
Weighted average common shares outstanding, basic | 54,743,490 | 54,429,023 |
Weighted average common shares outstanding, diluted | 54,743,490 | 54,429,023 |
Comprehensive loss: | ||
Net loss | $ (102,062) | $ (136,125) |
Unrealized gain (loss) on marketable securities | 923 | (553) |
Comprehensive loss | $ (101,139) | $ (136,678) |
Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 21,709 | $ 34,601 |
Marketable securities | 92,585 | 155,009 |
Prepaid expenses and other current assets | 923 | 926 |
Prepaid research and development | 2,742 | 6,508 |
Total current assets | 117,959 | 197,044 |
Property and equipment, net | 15,295 | 22,515 |
Right of use assets - operating leases | 16,858 | 19,723 |
Other assets | 433 | 4,267 |
Total assets | 150,545 | 243,549 |
Current liabilities: | ||
Accounts payable | 1,298 | 4,065 |
Accrued expenses and other current liabilities | 11,670 | 11,011 |
Operating lease liabilities | 3,373 | 3,275 |
Total current liabilities | 16,341 | 18,351 |
Operating lease liabilities - noncurrent | 22,921 | 23,832 |
Total liabilities | 39,262 | 42,183 |
Commitments and contingencies (note 10) | ||
Stockholders' equity: | ||
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both December 31, 2023 and December 31, 2022 | ||
Common stock, $0.0001 par value: 300,000,000 shares authorized; 54,944,130 shares issued and outstanding at December 31, 2023 and 54,614,690 shares issued and outstanding at December 31, 2022 | 5 | 5 |
Additional paid-in capital | 705,789 | 694,733 |
Accumulated other comprehensive income (loss) | (43) | (966) |
Accumulated deficit | (594,468) | (492,406) |
Total stockholders' equity | 111,283 | 201,366 |
Total liabilities and stockholders' equity | $ 150,545 | $ 243,549 |